Celltex Muscles Ethics Professor For Contacting FDA
By Ed Silverman,
Pharmalot
| 03. 12. 2012
Over the past month, a controversy erupted involving a stem cell company called Celltex Therapeutics and a newly hired executive, Glenn McGee. The issue centered on the confusing circumstances in which he was listed as the editor-in-chief of a bioethics journal at the same time that he began his job at Celltex, which has ties to a controversial stem cell company in South Korea called RNL Bio (
see this).
Celltex Therapeutics - which was co-founded by Stan Jones, the same surgeon who treated Texas Governor Rick Perry for back pain with unapproved adult stem cells - has a partnership deal with RNL Bio. And RNL Bio, which has marketed its stem cell treatments in various countries, made headlines nearly two years ago after patient deaths were reported in China and Japan. The International Cellular Medicine Society conducted a review, co-headed by McGee, which largely exonerated RNL.
This thorny episode, which prompted McGee to resign from Celltex (
look here), was chronicled by a pair of bioethics professors at the University of Minnesota, both of whom have now...
Related Articles
By Julia Black and Margaux MacColl, The Information [cites CGS' Katie Hasson] | 07.19.2024
When venture capitalist Jack Abraham first began dating his wife, Gabriella Massamillo, he insisted on one condition: that when they were ready to have children, she’d be willing to conceive using in vitro fertilization. Abraham had lost both his mother...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Emma McDonald Kennedy
| 07.11.2024
Louise Perry’s recent article in The Spectator cautions against “The quiet return of eugenics,” a threat she locates in preimplantation genetic testing for polygenic disorders. The technology is billed as a way for parents undergoing IVF to select which embryo to implant based on information about each embryo’s genetic risk factors and traits. These reports, she says, give parents “a very full picture of the adult that embryo could become”––from their child’s risk of developing different diseases to their “likely...